Biogen Reports (PERFUSE) Study Results of SB2 (biosimilar, infliximab) for Chronic Inflammatory Rheumatic Disease
Shots:
- The (PERFUSE) non-interventional study evaluating infliximab (IFX) biosimilar SB2 in 1233 adult patients, showed that SB2 was safe & effective in IFX-naïve patients and in patients who transitioned from prior infliximab reference or biosimilar
- Persistence on SB2 in the IFX-naïve/IFX reference/IFX biosimilar cohorts (59%/75%/85% for RA); (64%/87%/83% for PsA) & (56%/80%/80% for axSpA), respectively during 12mos. period. The study was published in Rheumatology Advances in Practice
- No concerns of immunogenicity & new safety signals were reported with no clinical differences in clinical effectiveness in patients switched from IFX reference or IFX biosimilar to SB2, 56% of IFX-naïve patients continued on SB2 treatment at 12mos. with no changes in the dosing regimen
Ref: Cente For Biosimilars | Image: Biogen
Related News:- Biogen and Ionis Receive the US FDA’s Approval of Qalsody (tofersen) for the Treatment of Amyotrophic Lateral Sclerosis
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
